Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
Top Cited Papers
- 30 August 2005
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 80 (1) , 19-32
- https://doi.org/10.1016/j.schres.2005.07.014
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtypeBipolar Disorders, 2004
- The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophreniaLife Sciences, 2004
- Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesThe Journal of Clinical Psychiatry, 2004
- Definition of Metabolic SyndromeCirculation, 2004
- Role of fibrates in reducing coronary risk: a UK ConsensusCurrent Medical Research and Opinion, 2004
- Changes in body mass index for individuals with and without schizophrenia, 1987–1996Schizophrenia Research, 2002
- Increased visceral fat distribution in drug-naive and drug-free patients with schizophreniaInternational Journal of Obesity, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Excess mortality of schizophreniaThe British Journal of Psychiatry, 1997
- Mortality Among Patients With SchizophreniaSchizophrenia Bulletin, 1996